GMJ Briefs
What Clinicians Need to Know: Three Critical Findings from the Zanidatamab HER2+ Gastric Cancer Trial
Zanidatamab's dual HER2 targeting mechanism, superior survival outcomes, and manageable safety profile position it as a promising new treatment option.
First Major Bay Area Longevity Festival Signals Industry Growth and Maturation
The Bay Area's first major longevity festival demonstrates the field's transition from niche research to mainstream public engagement and industry…
What Clinicians Need to Know About Alpha-Synuclein PET Imaging
New alpha-synuclein tracer enables preclinical Parkinson's detection and objective disease confirmation through molecular imaging.
What Patients with Advanced Heart Failure Should Know About Emerging Stem Cell Therapies
First-in-human trial demonstrates stem cell patches improve heart function and exercise capacity with excellent safety profile.
What You Need to Know About Cardiac Patch Therapy: Three Key Advances Reshaping Heart Repair
Three key advances in cardiac patch therapy—tissue integration, multiple cellular approaches, and personalized patient-derived patches—are transforming heart repair possibilities.
What Physicians and Patients Should Know About Emerging Stem Cell Heart Patch Therapy
Stem cell heart patches offer advanced heart failure patients meaningful cardiac function improvement with favorable safety—Phase II trials expected late…
Three Essential Points About GSK’s Hepatitis B Breakthrough
GSK's hepatitis B breakthrough combines improved functional cure rates, innovative RNA technology, and imminent phase 3 trials.
The 400-Kilometre Journey: How One Researcher’s Career Impacts Global Pertussis Control
With 24.1 million annual pertussis cases and 160,700 deaths globally, Dr. Hozbor's molecular research addresses critical vaccine effectiveness gaps.